FDA Approves BIMZELX[®] for Severe Plaque Psoriasis Treatment

The U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx), developed by UCB, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes. Clinical trials showed that a high percentage of patients treated with bimekizumab achieved clear or almost clear skin, with some achieving complete clearance. Psoriasis affects over 7.5 million adults in the U.S., and the approval of bimekizumab provides a new treatment option for patients.